Astellas Pharma (ALPMY) News Today → If you have $2,500 bucks… check this out (From DTI) (Ad) Free ALPMY Stock Alerts $9.55 +0.01 (+0.10%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 59.4%marketbeat.com - April 26 at 7:36 AMAstellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidancemsn.com - April 25 at 8:26 AMEuropean Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatmentmarkets.businessinsider.com - April 23 at 9:32 PMAstellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Settingprnewswire.com - April 23 at 7:30 PMTakeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programsmarkets.businessinsider.com - April 22 at 7:37 AMAstellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low at $9.15marketbeat.com - April 16 at 7:36 PMU.S. Stocks Erase Early Gainsfinance.yahoo.com - April 15 at 7:31 PMStocks Lose Steam to Start Week; Goldman Rises After Earningsfinance.yahoo.com - April 15 at 2:31 PMStock Futures Up With Goldman Earnings in Focusfinance.yahoo.com - April 15 at 9:31 AMAstellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month Low at $10.28marketbeat.com - April 8 at 5:43 PMAstellas Pharma Inc ADRmorningstar.com - April 4 at 2:19 PMChina NMPA accepts Astellas’ sBLA for urothelial cancer treatmentmsn.com - March 29 at 10:49 PMShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Grows By 51.6%marketbeat.com - March 29 at 8:22 AMAstellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In Chinamarkets.businessinsider.com - March 28 at 9:23 PMChina's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancerfinance.yahoo.com - March 28 at 9:23 PMAstellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancerfinanznachrichten.de - March 26 at 5:13 PMAstellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophyfinanznachrichten.de - March 26 at 5:13 PMAstellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancerfinance.yahoo.com - March 26 at 5:13 PMAstellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophyfinance.yahoo.com - March 26 at 5:13 PMAstellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Settingprnewswire.com - March 22 at 8:00 AMQ4 2023 Taysha Gene Therapies Inc Earnings Callfinance.yahoo.com - March 20 at 4:32 PMFDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Childrenfinance.yahoo.com - March 11 at 1:30 PMUbiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeuticsbusinesswire.com - March 11 at 5:27 AMAstellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japanprnewswire.com - March 3 at 6:31 PMAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Below 50-Day Moving Average of $11.51marketbeat.com - February 27 at 4:34 AMPADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancerfinance.yahoo.com - February 15 at 8:38 PMAstellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeuticsfinance.yahoo.com - February 15 at 8:38 PMAstellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeuticsprnewswire.com - February 15 at 6:30 PMAstellas Makes Announcement about Management Structurefinance.yahoo.com - February 7 at 1:57 PMAstellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowlfinance.yahoo.com - February 1 at 7:47 AMAstellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatmentmarkets.businessinsider.com - January 31 at 12:30 AMAstellas Pharma Announces Collaboration With Mass General Brighammarkets.businessinsider.com - January 31 at 12:30 AMAstellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancerfinance.yahoo.com - January 31 at 12:30 AMAstellas Announces Strategic Collaboration with Mass General Brighamfinance.yahoo.com - January 30 at 7:30 PMAstellas Pharma Inc. ADRwsj.com - January 30 at 2:29 PMAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 57.1% in Januarymarketbeat.com - January 26 at 5:18 AMVivtex Enters Research Collaboration with Astellas Pharmatmcnet.com - January 23 at 1:58 PMAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Increase in Short Interestmarketbeat.com - January 11 at 10:41 AMASTELLAS PHARMA INC.: Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.finanznachrichten.de - January 9 at 10:33 PMFDA denies approval of Astellas gastric cancer drugmsn.com - January 9 at 7:31 AMFDA Issues Complete Response Letter For Astellas' Zolbetuximab In HER2-Negative Gastric Cancermarkets.businessinsider.com - January 8 at 8:52 PMUS FDA declines to approve Astellas' gastric cancer drugfinance.yahoo.com - January 8 at 8:52 PMAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 14.6% in Decembermarketbeat.com - January 1 at 10:38 AMWeek In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Dealseekingalpha.com - December 31 at 5:58 AMElpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage Engagersmarkets.businessinsider.com - December 28 at 6:35 AMAstellas and Elpiscience collaborate for novel bi-specific macrophage engagersmsn.com - December 28 at 6:35 AMAstellas Pharma Inc. - ADR (ALPMY) Price Target Increased by 5.40% to 18.58nasdaq.com - December 18 at 9:06 AMEMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Childrenfinance.yahoo.com - December 17 at 11:32 PMMerck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcevmarketwatch.com - December 15 at 6:05 PMUPDATE 2-US FDA approves Astellas' combination therapy for bladder cancerfinance.yahoo.com - December 15 at 6:05 PM Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 ALPMY Media Mentions By Week ALPMY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼0.450.33▲Average Medical News Sentiment ALPMY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼82▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BMRN News Today ALNY News Today GMAB News Today TEVA News Today VTRS News Today MKGAF News Today BGNE News Today KRTX News Today RDY News Today UTHR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
